Neoadjuvant Anti-PD-1 Strategy Prevails Over Adjuvant in Resectable Melanoma

(MedPage Today) -- PARIS--The randomized trial data have spoken, and they favor neoadjuvant immunotherapy over adjuvant treatment for resectable melanoma.
Neoadjuvant pembrolizumab (Keytruda) followed by surgery and additional pembrolizumab...